不调节的蛋白质 - - 化促进化应激和疾病进展心力衰竭与保存的喷射分数心力衰竭
Zhen Li1,2, Kyle B LaPenna3, Natalie D Gehred4
1School of Traditional Chinese Pharmacy (Z.L., X.Y.), China Pharmaceutical University, Nanjing, China.
Circulation research
|September 17, 2025
概括
化应激和失调的蛋白质S-化有助于心力衰竭与保存的喷射分数 (HFpEF). 超酸酶和酸酶酶的不平衡,而不仅仅是NO的生物可用性,推动了这种情况,表明了新的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 氧化信号传输 氧化信号传输
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭病原与高诱导氧化合成酶 (iNOS) 和蛋白质S-化有关.
- 氧化 (NO) 生物可用性,S-化酶的酶调节和HFpEF进展之间的精确相互作用尚未完全理解.
研究的目的:
- 研究HFpEF中化应激的分子机制.
- 检查NO信号的变化和HFpEF中蛋白质S-化调节的变化.
主要方法:
- 在HFpEF患者中的量化循环亚酸盐和亚硫醇.
- 使用心脏代谢HFpEF的动物模型来评估心脏功能,NO信号和酸盐物种.
- 采用单核RNA测序和蛋白质组分析来识别调节基因和S-化位.
主要成果:
- 在HFpEF患者中,酸盐醇含量升高,但酸盐含量保持不变.
- 动物模型显示NO生物可用性下降,化物种增加,HFpEF恶化.
- 观察到转基因酶HBb的上调和Trx2和GSNOR的异常功能,导致细胞RxNO升高和心脏和外围组织中的S-基化失调.
结论:
- 在心脏代谢性HFpEF中,化应激和失调的蛋白质S-化存在于心脏和外周器官中.
- 病态的S-化是由于化酶和化酶功能之间的不平衡引起的,而不仅仅是由于NO的生物可用性变化.
- 恢复生理学S-化和NO信号可能为HFpEF提供治疗策略.
相关概念视频
01:29Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
541
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
541
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:28Nitric Oxide Signaling Pathway
6.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.2K
01:30Coronary Artery Disease I: Introduction
890
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
890